Arrowstreet Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Arrowstreet Capital’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$491K	Sell	265,562 -569,008	-68%	-$1.39M	﹤0.01%	1759
2026 Q1	$1.78M	Sell	834,570 -205,898	-20%	-$490K	﹤0.01%	1423
2025 Q4	$2.53M	Buy	1,040,468 +143,615	+16%	+$509K	﹤0.01%	1337
2025 Q3	$3.4M	Buy	896,853 +758,709	+549%	+$2.22M	﹤0.01%	1309
2025 Q2	$343K	Buy	+138,144	New	+$266K	﹤0.01%	1814

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Arrowstreet Capital's BDTX Position: Q2 2026 in Review

Arrowstreet Capital reduced its Black Diamond Therapeutics (BDTX) stake by 68% in Q2 2026, selling an estimated $1.39M and leaving 265,562 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Arrowstreet Capital first reported a position in BDTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.4M in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Arrowstreet Capital held 265,562 shares of Black Diamond Therapeutics worth $491K as of Q2 2026.
Arrowstreet Capital sold 569,008 Black Diamond Therapeutics shares in Q2 2026, an estimated $1.39M.
Black Diamond Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1759 holding.
Arrowstreet Capital first reported a position in Black Diamond Therapeutics in Q2 2025 and has held it in 5 quarters since.
Arrowstreet Capital's Black Diamond Therapeutics position peaked at $3.4M in Q3 2025.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.